ATP nucleotidylation of creatine kinase.
Creatine kinase (CK) will autoincorporate radiolabel from [gamma32P]ATP and has thus been reported to be autophosphorylated. Also, in contrast to normal brain enzyme, CK in Alzheimer-diseased brain homogenate shows greatly decreased activity, abolished photolabeling with [32P]8N3ATP, and no detectable autoincorporation of radiolabel by [gamma32P]ATP. Surprisingly, our studies with both human brain and purified CK showed that [alpha32P]ATP, [gamma32P]ATP, [alpha32P]ADP, [2,8H3]ATP, [gamma32P]2',3'-O-(2,4, 6-trinitrophenyl)-ATP, and [gamma32P]benzophenone-gammaATP all autoincorporate radiolabel into CK with good efficiency. This demonstrates that the gamma-phosphate and the 2' and 3' hydroxyls are not involved in the covalent linkage and that all three phosphates, the ribose and base of the ATP molecule are retained upon autoincorporation (nucleotidylation). Treatment with NaIO3 to break the 2'-3' linkage effected total loss of radiolabel indicating that nucleotidylation resulted in opening of the ribose ring at the C1' position. Nucleotidylation with increasing [alpha32P]ATP at 37 degrees C gives an approximate k0.5 of 125 microM and saturates at 340 microM nucleotide. Modification of 8-10% of the copy numbers occurs at saturation, and CK activity is inhibited to approximately the same degree. Low micromolar levels of native substrates such as ADP, ATP, and phosphocreatine substantially reduce [alpha32P]ATP nucleotidylation. In contrast, AMP, GTP, GMP, NADH, and creatine did not effectively reduce nucleotidylation. When [alpha32P]ATP-nucleotidylated or [alpha32P]8N3ATP-photolabeled CK is treated with trypsin a single, identical radiolabeled peptide (V279-R291) is generated that comigrates on reverse phase HPLC and Tris-tricine electrophoresis. Nucleotidylation into this peptide was prevented 86% by the presence of ATP. We conclude that CK is nucleotidylated within the active site by modification at the C1'position and that autophosphorylation of this enzyme does not occur.
David
S S
SS
Department of Chemistry, University of Kentucky, Lexington 40506-0055, USA.
Haley
B E
BE
D000255:Adenosine Triphosphate / Q000031:analogs & derivatives / Q000037:antagonists & inhibitors / Q000378:metabolism*; D000544:Alzheimer Disease / Q000201:enzymology / Q000378:metabolism; D000818:Animals; D001386:Azides / Q000037:antagonists & inhibitors / Q000378:metabolism; D001923:Brain Chemistry; D002851:Chromatography, High Pressure Liquid; D003401:Creatine / Q000737:chemistry / Q000378:metabolism; D003402:Creatine Kinase / Q000037:antagonists & inhibitors / Q000378:metabolism*; D004591:Electrophoresis, Polyacrylamide Gel; D004789:Enzyme Activation; D005998:Glycine / Q000031:analogs & derivatives; D006801:Humans; D007461:Iodoacetates / Q000737:chemistry; D007527:Isoenzymes; D018482:Muscle, Skeletal / Q000201:enzymology; D009713:Nucleotidyltransferases / Q000037:antagonists & inhibitors / Q000378:metabolism*; D010084:Oxidation-Reduction; D010455:Peptides / Q000378:metabolism; D010761:Phosphorus Radioisotopes; D019920:Photoaffinity Labels / Q000378:metabolism; D011817:Rabbits; D013379:Substrate Specificity; D013696:Temperature; D013997:Time Factors; D014325:Tromethamine; D014357:Trypsin / Q000378:metabolism
C095967:2-azido-2',3'-O-(2,4,6-trinitrophenyl)adenosine 5'-triphosphate; C026397:3'(O)-(3-(N-(4-azido-2-nitrophenyl)amino)propionyl)-8-azidoadenosine 5'-triphosphate; D001386:Azides; D007461:Iodoacetates; D007527:Isoenzymes; D010455:Peptides; D010761:Phosphorus Radioisotopes; D019920:Photoaffinity Labels; D014325:Tromethamine; C033901:3'-O-(4-benzoyl)benzoyladenosine 5'-triphosphate; D000255:Adenosine Triphosphate; D003402:Creatine Kinase; D009713:Nucleotidyltransferases; D014357:Trypsin; D003401:Creatine; D005998:Glycine; C100184:tricine